Back

Lower dose radiotherapy did not alter cardiac function and was not pro-arrhythmic: results of the small prospective HALO trial

8 April 2024 (11:30 - 12:15)
Organised by: Logo
Congress Presentation Part of: Ventricular tachycardia 3 Radiotherapy EHRA Premium Access EHRA 2024 European Heart Rhythm Association (EHRA)

About the speaker

Photo
Mr Wiert Hoeksema

Amsterdam University Medical Centre (AUMC), Amsterdam (Netherlands (The))

8 More presentations in this session

Presentation thumbnail
Modification of deceleration zones and late potentials after ventricular tachycardias substrate ablation
Doctor P. China (Mestre-Venice, IT)
Abstract Slides Video
Presentation thumbnail
An optimized multisource acquisition and registration workflow for imaging guided ventricular tachycardia ablation
Doctor M. Parollo (Pisa, IT)
Abstract Slides Video
Presentation thumbnail
The evaluation of the efficacy of automated peak frequency annotation algorithm for the identification of critical isthmus of ventricular tachycardia and deceleration zones
Professor H. Yorgun (Ankara, TR)
Abstract Slides Video
Presentation thumbnail
Genotype, phenotype and outcomes of patients with hypertrophic cardiomyopathy referred for ablation of ventricular tachycardia
Doctor A. Meretta (Leiden, NL)
Abstract Slides Video
Presentation thumbnail
Characterization of ventricular tachycardia ablation in end-stage heart failure patients with left ventricular assist device (CHANNELED-Registry)
Doctor J. van den Bruck (Cologne, DE)
Abstract Slides Video

Access the full session

Session thumbnail
Ventricular tachycardia 3

The Event

Event poster

EHRA 2024

8 April 2024 11:30 CET
You may be interested in
thumbnail
Congress Presentation
Stereotactic arrhythmia radiotherapy for refractory ventricular tachycardia: Interim safety and efficacy results from the ongoing prospective STARNL-2 trial
thumbnail
Congress Presentation
Cardiovascular safety of modern radiotherapy techniques in breast cancer
thumbnail
Congress Presentation
Discovery of novel imaging biomarkers for cardiotoxicity in a prospective longitudinal study of cancer patients receiving anthracyclines and chest radiotherapy